Vulnerable patients: burning questions in IBD
An interesting session at ECCO dealt with the patients for whom there is sparce data to guide their treatment – experts in the field gave their guidance to… read more.
An interesting session at ECCO dealt with the patients for whom there is sparce data to guide their treatment – experts in the field gave their guidance to… read more.
Managing multiple myeloma in elderly/frail patients Although multiple myeloma is a disease of old age, elderly patients vary a great deal in terms of fitness and ability… read more.
Preventing clonal evolution in multiple myeloma – evidence from clinical trials by Maria Dalby Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution… read more.
How monoclonal antibodies will change the treatment of multiple myeloma by Maria Dalby Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France Meletios Dimopoulos, University of Athens School of… read more.
by Bruce Sylvester: Researchers from a randomized phase III trial report that addition of temozolomide (Temodar) chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide,… read more.
by Bruce Sylvester: Anti-PD-L1 immunotherapy atezolizumab (TECENTRIQ) has shown efficacy in previously untreated patients with advanced bladder cancer who are ineligible for standard treatment with cisplatin.
by Gary Finnegan: Cholesterol levels – the most common risk factor for heart attacks – have decreased in northern Sweden over the last 20 years. Since medication only… read more.
by Gary Finnegan: Hospital admissions for first-time stroke increased in young adults in Denmark during the past two decades, according to new research in Journal of the American… read more.
Risk stratification in the older patient: what are our priorities? by Maria Dalby Professor Sonja Zweegman, VU University Medical Centre, Amsterdam, NL Biological age and frailty, rather than… read more.
Risk stratification in the older patient: what are our priorities? by Maria Dalby Professor Sonja Zweegman, VU University Medical Centre, Amsterdam, NL Biological age and frailty, rather than… read more.
Stopping drugs – by Maria Dalby Charles Lees (Edinburgh, UK) Medication constitutes a large part of the IBD exposome, and stopping drug treatment should be a therapeutic goal… read more.
by Gary Finnegan: Good news in the battle against cancer: death rates from leukaemia among people of all ages in Europe are falling.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.